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EGFR mutation is cost-effective with a willingness to pay above $1379.49 per extra 
progression-free month. In the testing strategy, patients with mutation positive disease 
treated with geﬁtinib beneﬁted from an extra 4.52 progression-free months compared 
to positive patients in the non-testing strategy.
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OBJECTIVES: To utilize data on a large population-based cohort of elderly non-
Hodgkin’s lymphoma (NHL) patients treated with chemotherapy to measure the 
cost-effectiveness (as measured as cost per life-year saved) of white blood cell growth 
factor (CSF) use in a real-world setting METHODS: We identiﬁed 13,203 NHL 
patients from the SEER-Medicare database diagnosed from 1992 to 2002 who 
received chemotherapy within 12 months of diagnosis. Patients were followed from 
initial chemotherapy date until death or end of study period (October 31, 2006). 
Effectiveness of CSF use (primary and secondary prophylaxis) was measured as 
improved overall survival. Costs were estimated by summing reimbursement amounts 
derived from claims. Cost-effectiveness was estimated by modeling the joint inﬂuence 
of CSF use on costs and effectiveness using a propensity-score net monetary beneﬁt 
approach. RESULTS: Primary prophylactic CSF use was cost-effective at lower will-
ingness to pay thresholds, whereas at higher thresholds, not providing prophylactic 
CSF became the cost-effective strategy. For secondary prophylactic CSF use following 
neutropenia, fever, and/or infection, the opposite trend was observed. For low willing-
ness to pay thresholds (less than $20,000 per life year gained), not administering CSF 
was the cost-effective strategy, while CSF use became cost-effective as willingness to 
pay increased (from $100,000+ per life year gained). CONCLUSIONS: To our knowl-
edge this is the ﬁrst population-based study to empirically measure the cost-effective-
ness of CSF among cancer patients treated with chemotherapy. Results suggest that 
CSF use as primary or secondary prophylaxis may be cost-effective depending on 
society’s willingness to pay for improvements in outcomes.
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OBJECTIVES: Erlotinib (Tarceva®) is the ﬁrst and only oral targeted therapy with 
both proven survival and symptom beneﬁt in 2nd and 3rd-line treatment of patients 
with IIIb/IV metastatic NSCLC. We evaluated the cost-effectiveness of erlotinib versus 
pemetrexed, from the National Health Insurance House (NHIH) perspective. 
METHODS: A Markov model was developed using published results from two ran-
domized clinical trials (BR.21 study and Phase III pemetrexed vs. docetaxel) evaluating 
progression-free survival (PFS) and overall survival (OS) in patients with NSCLC. 
Rates of disease progression were modeled using Kaplan-Meier analysis over 24 
months; OS was further extrapolated to 36 months using a Weibull parametric func-
tion. Key assumption in the model was that PFS and OS are similar, due to lack of 
direct comparison studies. Utility values for the PF and progressed health states were 
derived from a utility study conducted in the UK. Direct medical costs were included. 
Resources were estimated using expert opinion from 4 oncology centers. Unit costs 
(for 2009) were derived from Romanian retail prices for drugs, diagnostic and moni-
toring tests and procedures, hospitalizations and post-treatment costs. Costs and 
outcomes were discounted by 3.5%. Sensitivity analysis was performed. RESULTS: 
The total cost per patient treated with erlotinib (47,762 Rol) is much lower than 
pemetrexed cost (76,322 Rol) due to lower drug cost, lower adverse events costs, as 
well as avoidance of administration costs of drug. Analysis showed that although 
clinical beneﬁt is assumed to be the same, there are on average 28,561 Rol saved per 
patient treated with erlotinib instead of pemetrexed. Sensitivity analysis showed that 
even in case of lowering pemetrexed drug cost by 27% (∼two administrations free), 
erlotinib remains a cost-saving therapy. CONCLUSIONS: This study demonstrates 
that erlotinib is a dominant treatment strategy when compared to pemetrexed, allow-
ing for important savings.
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OBJECTIVES: To estimate the probability that epoetin alfa is more cost-effective than 
darbepoetin alfa for the treatment of chemotherapy related anemia in Sweden using 
a cost-effectiveness simulation model. METHODS: Studies for recommended dosing 
regimens of epoetin alfa and darbepoetin alfa were identiﬁed from the literature and 
used to assess haematopoietic response rates, dose escalation rates and the mean 
number of RBC transfusions required in chemotherapy patients. A simulation model 
including estimates of proportions, means and variances of these outcomes was estab-
lished to estimate costs and effectiveness of these agents over 12 weeks. Published 
Swedish unit costs were used. Haematopoietic response rates, deﬁned as Hb level 
≥12 g/dl or an increase from baseline of ≥2 g/dl without a history of transfusion 28 
days prior to response, were used as the effectiveness measure.The probability of 
epoetin alfa exhibiting economic dominance (higher effectiveness and lower cost) and 
also being more cost-effective than darbepoetin alfa was estimated. Six separate sen-
sitivity analyses were conducted where differet costs items, variances/correlations and 
etsimted response rates was tested. RESULTS: According to this model, epoetin alfa 
is associated with greater effectiveness than darbepoetin alfa. Mean haematopoietic 
response rate was 49.86% for epoeting alfa compared to 41.38% in darbepoetin alfa. 
Epoetin alfa is also associated with lower costs than darbepoetin alfa, Sek 31,661 
compared to Sek 43,369 over 12 weeks of therapy. The probability that epoetin alfa 
exhibits economic dominance over darbepoetin alfa is estimated at 92.9% and the 
probability that epoetin alfa is more cost-effective is estimated at 99.9%. Sensitivity 
analyses suggest that the model is robust and, within the margins of uncertainty, not 
sensitive to modiﬁcations in the underlying estimates. CONCLUSIONS: This analysis 
suggests that epoetin alfa should be considered ﬁrst for treating chemotherapy-related 
anaemia given its cost-effectiveness proﬁle. Comparative efﬁcacy of these agents 
should be further assessed in future head-to-head studies.
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OBJECTIVES: With the recent updates of clinical guidelines of the National Compre-
hensive Cancer Network (NCCN) and the American Society of Clinical Oncology 
(ASCO), aromatase inhibitors have been included in the management of early-stage 
breast cancer. There has been a great interest to understand the cost-effectiveness of 
this new alternative therapy which is becoming an “optimal therapy” for breast 
cancer. The objective of this study is to review the cost-utility studies on aromatase 
inhibitors for the treatment of early-stage breast cancer and compare reported incre-
mental cost-effectiveness ratios (ICERs). METHODS: We conducted a literature for 
cost-utility studies on anastrazole, letrozole and exemestane. We reviewed the papers 
to extract the information on intervention, comparator, ICER, country, perspective, 
time horizon and clinical data used. For the comparison of reported ICERs, we con-
verted all currencies to US dollars by exchange rate for the cost-year used, then inﬂated 
the values to 2008. RESULTS: A total of 20 papers were identiﬁed (8 on anastrazole, 
8 on letrozole and 4 on exemestane). All studies were from health care perspective 
and sponsored by manufacturers. The time horizon modeled ranged from 7.5 years 
to lifetime, however majority of the studies modeled lifetime. The studies were from 
EU countries and North America such as US, Canada, Belgium, Italy, Sweden and 
UK. The mean ICER values were $24,932 for anastrazole, $21,113 for letrozole and 
$21,428 for exemestane. CONCLUSIONS: The mean ICERs for all three aromatase 
inhibitors are below $25,000; hence they appear to be cost-effective compared to 
tamoxifen therapy for the treatment of early-stage breast cancer.
PCN80
A SYSTEMIC REVIEW OF COST-EFFECTIVENESS OF PROSTATE-
SPECIFIC ANTIGEN (PSA) IN PROSTATE CANCER SCREENING
An JJ1, Wu J1, Huang JT2, Nichol MB1
1University of Southern California, Los Angeles, CA, USA, 2Beckman Coulter Inc, Brea, 
CA, USA
OBJECTIVES: Controversy exists regarding the clinical and economic value of pros-
tate cancer (PCa) screening. Our objective is to summarize cost-effectiveness studies 
on Pca screening with PSA. METHODS: We systematically searched the English-
language literature for cost-effectiveness analyses (CEA) on PSA screening programs 
published between 1994–2009 using Medline and other databases. We collected data 
related to methods, screening population, screening strategies, and reporting of results. 
RESULTS: We identiﬁed 10 CEA in PCa screening using PSA, 30% of the studies 
investigated efﬁcacy of PSA on PCa detection, and 70% for efﬁcacy of PSA on both 
PCa detection and consequent treatments. All studies were based on either decision 
tree (60%) or Markov models (40%). Majority of studies only modeled single-episode 
screening (80%). The screening population included men age 40–79 years old, high 
PCa risk sample, or Medicare population. Four types of screening strategies were 
compared: 1) no screening vs. PSA, or PSA combined with digital rectal examination 
(DRE); 2) different thresholds of normal PSA; 3) isoforms of PSA (PSA, free PSA, 
complexed PSA); 4) different screening intervals. Method of cost-effectiveness 
measures varied from studies. Outcomes were presented as costs/quality adjusted life 
years (QALY) (30%), costs/life-years saved (40%), costs/curable cancers (20%), costs/
detected cancer (10%). Only ﬁve studies originated in U.S. As compared to no screen-
ing, four studies reported an incremental cost-effectiveness ratio for screening with 
PSA or combined with DRE that ranged from $12,502 to $65,909/life-year saved in 
Medicare population aged 65–69 years, and general population aged 70–79 years, 
respectively. One study reported that PSA- alone screening was dominated by no 
screening in the general population aged 50–79 years. CONCLUSIONS: Economic 
evaluation of PSA in Pca screening remains limited. Cost-effectiveness ratios reported 
from studies varied from screening populations, calendar year, and country original, 
which made the comparisons difﬁcult.
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OBJECTIVES: Hepatocellular carcinoma (HCC) is the ﬁfth cause of dead from cancer 
worldwide. Hepatitis B virus infection is the important risk of HCC. Alpha fetoprotein 
(AFP) and liver ultrasound had been introduced as semi-annual screening test for HCC 
in human with hepatitis B surface antigen positive or patients with chronic hepatitis 
B. However, the cost-effectiveness of this screening is not well deﬁned. Our objective 
was to explore the cost-effectiveness of semi-annual HCC screening using AFP and 
liver ultrasound from societal perspective compared with no screening. METHODS: 
With a Markov model, we simulated the four health states of natural history of HCC 
which were no HCC state, resectable HCC state, unresectable HCC state and death 
state with 6-month cycle lenght. The based case decision model was run for male 
patients with age of 51 that is mean age of screening group. Cost and outcomes were 
discounted at a 3% annual rate. Probabilistic sensitivity analysis was performed. 
RESULTS: For semi-annual HCC screening, the incremental cost effectiveness ratio 
(ICER) which compared with no screening was US$14,111 (95%CI US$13,650–
US$14,573) per quality adjusted life year (QALY) for male chronic HBV patients. 
CONCLUSIONS: AFP with liver ultrasound is not cost effective for semi-annual 
screening HCC in patients with hepatitis B surface antigen positive or patients with 
chronic hepatitis B, according to the Thai threshold that ICER of cost-effective inter-
vention should not be exceed US$ 9000 per QALY.
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OBJECTIVES: New treatments for advanced NSCLC offer clinical beneﬁts over 
standard chemotherapy, however it is important they demonstrate value for money. 
Bevacizumab with chemotherapy improves survival and time to progression in patients 
with advanced NSCLC compared to chemotherapy alone. Pemetrexed and cisplatin 
has shown survival improvements over gemcitabine plus cisplatin. In the light of 
gemcitabine generic pricing, the aim of this analysis was to provide an update on how 
the treatment costs of bevacizumab plus cisplatin and gemcitabine (BCG) compare 
with pemetrexed plus cisplatin (PC) therapy in Germany. METHODS: A 3-state 
Markov model was used to evaluate the costs of treating advanced or recurrent 
NSCLC with either BCG or PC induction therapy. The model assumes patients move 
between states according to transition probabilities derived from the efﬁcacy data 
(progression-free survival) from the pivotal trials. Drug costs assume chemotherapy 
was given for up to 6 cycles, but that single agents pemetrexed and bevacizumab 
(7.5 mg/kg) were administered until progression. RESULTS: The monthly drug costs 
for BCG and PC therapy were 35764 and 36456, respectively; a saving of 3692 per 
month with BCG. The mean monthly costs of administration were 3205 for BCG and 
3153 for PC (a difference of 352). CONCLUSIONS: With the availability of generic 
gemcitabine during 2009, triplet therapy with bevacizumab has increased the potential 
monthly cost savings compared to doublet chemotherapy with pemetrexed. From a 
budget perspective bevacizumab should be considered as the targeted therapy of choice 
for patients with advanced NSCLC in Germany.
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OBJECTIVES: The aim of present analysis was to assess cost-effectiveness of leno-
grastim in comparison with other G-CSFs—ﬁlgrastim and pegﬁlgrastim in Polish 
settings (threshold is about 100,095 PLN). METHODS: Analysis covered time horizon 
of one chemotherapy cycle. A public payer perspective was adopted for cost analysis. 
The costs included were based on Polish NHF reference costs list. Data on time to 
ANC recovery, number of days with fever, length of hospital stay and antibiotics use 
were obtained from randomized controlled trials (RCTs) identiﬁed in the conducted 
systematic review. These included trials on prophylactic G-CSF use as well as trials in 
which only patients with neutropenia were included. Equations describing costs and 
QALY according to neutropenia and fever length, hospital stay and antibiotic use were 
established. RESULTS: Estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0035 (CI95%[0.0023; 0.0048]), compared to pegﬁlgrastim is 0.0039 
(CI95%[0.0026; 0.0052]). Total costs difference between lenograstim and ﬁlgrastim is 
−2015 PLN (CI95%[−3004; −938]) and compared to pegﬁlgrastim is −3236 PLN 
(CI95%[−4125; −2259]). Probability of lenograstim being cost-effective over ﬁlgrastim 
is 99.98% and over pegﬁlgrastim is 100%. Taking into account only trials where 
G-CSFs were used in neutropenia prophylaxis estimated QALY difference between 
lenograstim and ﬁlgrastim is 0.0029 (CI95%[0.0015; 0.0044]), compared to pegﬁlgras-
tim is 0.0031 (CI95%[0.0017; 0.0047]). Total costs difference between lenograstim and 
ﬁlgrastim is −1720 PLN (CI95%[−2935; −487]) and compared to pegﬁlgrastim is −3097 
PLN (CI95%[−4168; −1943]). Probability of lenograstim being cost-effective over ﬁl-
grastim is 99.81% and over pegﬁlgrastim is 100%. CONCLUSIONS: Lenograstim is 
dominant over ﬁlgrastim and pegﬁlgrastim. Acknowledgements: This analysis was 
supported by Sanoﬁ-Aventis.
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OBJECTIVES: To conduct a cost effectiveness analysis of anti-EGFR treatment 
regimes for the treatment refractory mCRC. Clinical trial data was available and 
utilized to examine panitumumab monotherapy and to compare cetuximab mono-
therapy vs cetuximab + irinotecan therapy, while indirect clinical trial data compared 
cetuximab based therapies with panitumumab monotherapy. METHODS: A Markov 
model comprising of three health states (stable disease, progressive disease and death), 
was developed from an US societal perspective to estimate economic implications of 
weekly anti-EGFR treatments for 52 weeks for 1000 treatment refractory mCRC 
patients. Transition probabilities were estimated based on available clinical literature 
data for each treatment. Therapy cost, health utilities, direct and indirect costs were 
based on published literature and national health care databases. Cost parameters 
were reported based on 2009 US dollars with a 3% discount rate. RESULTS: The 
analyses yielded an ICER of $249,035/QALY for cetuximab monotherapy vs cetux-
imab + irinotecan, an ICER of $266,196/QALY for cetuximab monotherapy vs. 
panitumumab, an ICER of $250,992/QALY for cetuximab + panitumumab and an 
ICER of $773,978/QALY for panitumumab vs. best supportive care (placebo). 
Through strictly increasing rankings of the ICERs, we ﬁnd best supportive care to be 
most cost effective therapy, followed by panitumumab monotherapy, cetuximab 
monotherapy and cetuximab + irinotecan therapy; however, changes in model param-
eters may inﬂuence the rankings of the treatment regimes. CONCLUSIONS: Based on 
the willingness to pay threshold of $150,000/QALY, treating treatment refractory 
mCRC patient with anti-EGFR agents is not cost effective. However, since the clinical 
literature lacks comprehensive head to head clinical trial amongst all anti-EGFR 
agents, further research is necessary.
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OBJECTIVES: Treatment failure patients in various disease areas are often treated by 
multiple rounds of therapy. However new treatment options are emerging that have 
potential to replace that treatment with single-agent or single round of combination 
treatment. It is challenging to demonstrate cost effectiveness of these new agents, 
especially when comparator is not one single regimen but sequential treatment. We 
present here our results from a study where we developed a model that can incorporate 
multiple rounds of treatment or relapses to estimate cost effectiveness of new emerging 
therapies. METHODS: Intervention was chosen as an emerging T-cell lymphoma drug 
candidate. Comparator was chosen as sequential treatment with 1–5 chemo regimens 
(called DHAP, ESHAP, ICE, HyperCVAD and EPOCH). All comparator chemo regi-
mens are generics and their prices were obtained from Medispan’s PriceRx. Interven-
tion’s price was assumed as median price of branded chemotherapy agents. Cost, 
efﬁcacy, adverse events and utilities were sourced and estimated from published studies 
for T and B-cell lymphoma. Relapses and number of chemo regimens for comparators 
were varied from 1–5. Sensitivity analyses were performed for all base calculations. 
RESULTS: Model results show that a new agent that can replace multiple rounds of 
treatment is relatively more cost effective that another agent that replaces relatively 
fewer rounds of treatments. Our base case incremental cost effectiveness with one 
chemo regimen as comparator was $262,908. However if there are 2,3,4 or 5 sequen-
tial rounds, the ICER values change to $223,078, $183,249, $143,420, and $103,591, 
respectively. CONCLUSIONS: For newer agents that are indicated for treatment 
failure patients, the use of sequential treatments as comparator can signiﬁcantly 
improve their cost effectiveness. The model approach described here can be used for 
Arthritis, Hepatitis C, and Diabetes and Oncology TF patients.
